Vanquish
Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group that develops, manufactures, commercializes, and distributes medicines, supplements, and medical devices in Mexico and selected international markets through five subsidiaries and over 2,500 SKUs.
- Company typePrivate
- Founded1979
- HeadquartersCiudad De Mérida, Mexico
- Headcount—
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Vanquish does
Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group headquartered in Mexico City, operating since 1979 across the full healthcare value chain through five wholly-owned subsidiaries plus the Emerge Lab brand. The group's core technology footprint is concentrated in solid oral and effervescent pharmaceutical formulations, manufacturing of advanced-technology medical devices, and the patented active ingredient Calcium Gluconolactate for osteoporosis treatment (patented 2002). Primary production assets are located in Civac, Morelos, where the original API and finished-dose manufacturing operations have been based for over four decades.
The company operates three interconnected business axes: (1) manufacturing of medicines and medical devices through Laboratorios Vanquish and Emerge Lab; (2) commercialization of licensed medicines and OTC supplements through Mirei Pharma, distribution to pharmacies and supermarkets, an in-house e-commerce pharmacy platform, and B2B licensing for domestic and international markets; and (3) integrated 4PL logistics operated by Vantage Servicios Integrales de Salud, distributing over 2,500 SKUs nationwide with cold and dry chain capabilities to public sector institutions, healthcare providers, and other pharmaceutical laboratories. The company entered international markets between 2019 and 2024 and has stated a strategic goal of ranking among the top five healthcare enterprises in Latin America by 2030.
Revenue is generated through a mix of one-time manufacturing contracts, licensing and royalty arrangements, managed logistics services, and direct e-commerce transactions. The customer base spans Mexican public sector procurement, private pharmacies, supermarket chains, healthcare institutions, and international B2B partners. Grupo Vanquish is founder-controlled and self-funded, with no disclosed external equity, debt, or public listing, and its ownership and corporate structure have not been reported as having undergone material change.
Vanquish firmographics
Firmographics- Name
- Vanquish
- Legal name
- Grupo Vanquish de México, S.A. de C.V.
- Website
- https://grupovanquish.com.mx
- Company type
- Private
- Founded year
- 1979
- Operating status
- Operating
- Short description
- Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group that develops, manufactures, commercializes, and distributes medicines, supplements, and medical devices in Mexico and selected international markets through five subsidiaries and over 2,500 SKUs.
- Ownership category
- akta.pro rank
Vanquish industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)
- akta.pro secondary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Vanquish is headquartered
LocationHeadquarters
- HQ city
- Ciudad De Mérida
- HQ country
- Mexico
- HQ region
- Latin America
Offices5 records
Markets served
Vanquish business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Manufacturing: Development and manufacturing of solid and effervescent oral medicines, and advanced technology medical devices
- Commercialization: Commercialization of licensed medicines and supplements for private and public markets through B2B models
- Distribution and Logistics: Integral logistics operations covering distribution of medicines and medical supplies nationwide with over 2,500 SKUs for public sector
- E-commerce: Dynamic e-commerce platform for pharmacy products serving end consumers
Go-to-market motion2 records
Distribution channels6 records
Marketing channels4 records
Vanquish product offering
Product offeringCore offering
Grupo Vanquish is a Mexican pharmaceutical group that develops, manufactures, and commercializes solid oral and effervescent medicines, OTC supplements, and advanced-technology medical devices through its subsidiaries Laboratorios Vanquish, Mirei Pharma, Vanquish Farmacéutica, and Emerge Lab. It also operates 4PL logistics services through Vantage Servicios Integrales de Salud, distributing medicines and medical supplies with over 2,500 SKUs across Mexico via cold and dry chain networks to public and private sector customers.
Product overview
Grupo Vanquish operates as an integrated pharmaceutical group with five subsidiaries offering a full-spectrum healthcare value chain. The portfolio centers on three core business axes: (1) Manufacturing through Laboratorios Vanquish and Emerge Lab, producing solid oral and effervescent medicines plus medical devices; (2) Commercialization via Mirei Pharma and the company's own licensing operations, distributing medicines and supplements through pharmacies, supermarkets, and e-commerce platforms to both private and public sectors; and (3) Logistics through Vantage Servicios Integrales de Salud, providing 4PL services with over 2,500 SKUs across cold and dry chain networks nationwide. The group also holds a patent for Calcium Gluconolactate for osteoporosis treatment (2002) and entered international markets in 2019.
Differentiator
Problem solved
Functional benefit
Products and services
- Manufacturing of Medicines and Medical Devices Contract and proprietary development and manufacturing of solid oral medicines, effervescent formulations, and advanced-technology medical devices through Laboratorios Vanquish and Emerge Lab facilities in Morelos, Mexico. Customers include private pharmaceutical companies and the Mexican public healthcare sector.
- Commercialization of Medicines and Supplements Licensing and B2B distribution of proprietary medicines, OTC supplements, and the Mirei Pharma brand portfolio to pharmacies, supermarkets, and international partners, plus a direct e-commerce pharmacy channel serving end consumers in Mexico.
- Integral Logistics Operations (4PL) Fourth Party Logistics services operated through Vantage Servicios Integrales de Salud, importing medical supplies from origin and delivering last-mile throughout Mexico with cold and dry chain capabilities. Manages over 2,500 SKUs of medicines and medical supplies for public sector healthcare institutions and pharmaceutical laboratories nationwide.
- Calcium Gluconolactate (Gluconolactato de Calcio) Active Ingredient Patented active pharmaceutical ingredient (principio activo) developed and patented by Grupo Vanquish for the treatment of osteoporosis, available for licensing and use in pharmaceutical formulations.
Quantifiable outcome
- Over 2,500 SKUs supplied to public sector
- +2 more outcomes
Companies that use Vanquish
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Vanquish technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vanquish partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Laboratorios Vanquish, S.A. de C.V.coreSubsidiary company of Grupo Vanquish, part of the pharmaceutical group structure including Grupo Vanquish de México, Mirei Pharma de México, Vantage Servicios Integrales de Salud, and Vanquish Farmacéutica
- Mirei Pharma de México, S.A. de C.V.coreSubsidiary company of Grupo Vanquish focused on pharmaceutical products and services
- Vantage Servicios Integrales de Salud, S.A. de C.V.coreSubsidiary company of Grupo Vanquish providing integrated healthcare services
- Vanquish Farmacéutica, S.A. de C.V.coreSubsidiary company of Grupo Vanquish focused on pharmaceutical operations
- Grupo Vanquish de México, S.A. de C.V.coreParent/holding company of Grupo Vanquish group, the main entity overseeing subsidiaries
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Vanquish competitors and assessment
Company assessmentBroad incumbents
- Bayer de México: Multinational pharmaceutical and consumer health incumbent operating broadly in Mexico; relevant benchmark for scale, regulatory capability, and consumer brand reach that Grupo Vanquish's OTC and portfolio strategies must compete against.
- Sanofi México: Multinational pharma with established Mexican manufacturing and strong public-sector franchise (vaccines, primary care); relevant benchmark for what a broad multinational incumbent offers versus a focused local player in the same public tenders.
- Pfizer México: Multinational pharmaceutical incumbent across prescription, vaccines, and public-sector supply in Mexico; comparable on tender participation and on serving government healthcare institutions at large scale.
Direct peers
- Laboratorios PiSA (Grupo PiSA): One of Mexico's largest integrated pharmaceutical groups with manufacturing, distribution, and public/private market commercialization across 2,000+ SKUs; most directly comparable peer given similar nationwide Mexican footprint and public-sector supply orientation.
- Laboratorios Silanes: Mexican pharmaceutical manufacturer with significant private and public sector presence; comparable on domestic manufacturing scale and on serving Mexican government drug procurement programs.
- Probiomed: Mexican biopharmaceutical manufacturer with biologics, generics, and public-sector supply capability; comparable on the combination of domestic API/finished-dose manufacturing and integration into Mexican institutional channels.
- Genomma Lab Internacional: Mexico-based OTC and consumer healthcare company with strong retail, supermarket, and pharmacy distribution; directly comparable on Mexican OTC channel strategy and brand-led commercialization.
Regional players
- Eurofarma: Brazilian pharmaceutical multinational with a growing LatAm footprint across manufacturing and distribution; most relevant regional peer for benchmarking Grupo Vanquish's stated Top-5 LATAM healthcare ambition by 2030.
- Grupo EMS: Brazilian pharmaceutical group with multi-country LatAm presence and broad generic/OTC portfolio; useful regional comparable for assessing how Grupo Vanquish's portfolio and channel strategy could translate outside Mexico.
Emerging players
- Laboratorios Chinoin: Mexican pharmaceutical manufacturer with branded generics and OTC presence; comparable niche player operating alongside Vanquish in Mexican private and OTC channels with similar therapeutic-area focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Vanquish social profiles
Digital presenceVanquish financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vanquish leadership team
Management profileNumber of profiles
Vanquish subsidiaries and ownership
Company hierarchySubsidiaries6 records
Vanquish funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vanquish M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vanquish
What does Vanquish do?
Grupo Vanquish is a Mexican pharmaceutical group that develops, manufactures, and commercializes solid oral and effervescent medicines, OTC supplements, and advanced-technology medical devices through its subsidiaries Laboratorios Vanquish, Mirei Pharma, Vanquish Farmacéutica, and Emerge Lab. It also operates 4PL logistics services through Vantage Servicios Integrales de Salud, distributing medicines and medical supplies with over 2,500 SKUs across Mexico via cold and dry chain networks to public and private sector customers.
Is Vanquish a public or private company?
Vanquish is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vanquish founded?
Vanquish was founded in 1979.
Where is Vanquish based?
Vanquish is headquartered in Ciudad De Mérida, Mexico, in the Latin America region.
How does Vanquish make money?
Four revenue lines are on record. Manufacturing is the primary driver. The others are commercialization, distribution and Logistics and E-commerce.
Who are Vanquish's main competitors?
Broad incumbents on record are Bayer de México, Sanofi México and Pfizer México. Direct peers are Laboratorios PiSA (Grupo PiSA), Laboratorios Silanes, Probiomed and Genomma Lab Internacional. Regional players are Eurofarma and Grupo EMS. Laboratorios Chinoin is listed as an emerging player.
Does Vanquish have an API?
No public API is recorded for Vanquish.
What industry is Vanquish in?
Vanquish's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor), with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.